Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of FIB Grifols for bleeding treatment and surgical bleeding management in congenital afibrinogenemia or severe hypofibrinogenemia
2018-004005-81Phase 3Terminated
- Sponsor
- Grifols
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Fibrinogen human in congenital afibrinogenemia and congenital hypofibrinogenemia, sponsored by Grifols. Primary endpoint: Primary efficacy endpoint. Started Sep 2020; status: terminated.
02
Drugs
Fibrinogen human
03
Conditions
congenital afibrinogenemiacongenital hypofibrinogenemia
Beyond the preview
Go deeper on 2018-004005-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004005-81.